Literature DB >> 3752976

Disposition of cefotaxime and desacetyl cefotaxime during continuous ambulatory peritoneal dialysis.

K L Heim, C E Halstenson, C M Comty, M B Affrime, G R Matzke.   

Abstract

The disposition of cefotaxime (CTX) and desacetyl cefotaxime (DAC) was studied in eight noninfected patients on continuous ambulatory peritoneal dialysis. Each patient received a single intravenous (i.v.) infusion and an intraperitoneal (i.p.) instillation of 2 g of CTX. Multiple blood and dialysate samples were collected during the 72-h period after drug administration. The half-life, steady-state volume of distribution, and total body clearance of CTX following i.v. administration were 2.2 +/- 1.0 h (mean +/- standard deviation), 0.17 +/- 0.03 liters/kg, and 81.0 +/- 31.0 ml/min, respectively. No significant differences were observed in these parameters after i.p. administration. The continuous ambulatory peritoneal dialysis clearances of CTX and DAC were 1.82 +/- 0.43 and 2.84 +/- 0.70 ml/min, respectively, after i.v. administration. The bioavailability of CTX after i.p. instillation was 74.6 +/- 21.3%. Peak peritoneal dialysate CTX and DAC concentrations of 264.3 and 25.8 mg/liter, respectively, were observed after i.p. dosing. Administration (i.v.) of 2 g every 12 h or i.p. instillation of 2 g every 24 h may be used for the treatment of i.p. infections with highly susceptible organisms (MIC less than 1.0 microgram/ml).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3752976      PMCID: PMC176426          DOI: 10.1128/AAC.30.1.15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Metabolism of cefotaxime in animals and man.

Authors:  J Chamberlain; J D Coombes; D Dell; J M Fromson; R J Ings; C M Macdonald; J McEwen
Journal:  J Antimicrob Chemother       Date:  1980-09       Impact factor: 5.790

2.  Pharmacokinetics of ceftizoxime in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  E D Burgess; A D Blair
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

3.  Noncompartmental determination of the steady-state volume of distribution for any mode of administration.

Authors:  D Perrier; M Mayersohn
Journal:  J Pharm Sci       Date:  1982-03       Impact factor: 3.534

Review 4.  Trimethoprim alone for treatment of urinary tract infection.

Authors:  H C Neu
Journal:  Rev Infect Dis       Date:  1982 Mar-Apr

5.  The cooperation of cefotaxime and desacetyl-cefotaxime with respect to antibacterial activity and beta-lactamase stability.

Authors:  M Limbert; G Seibert; E Schrinner
Journal:  Infection       Date:  1982       Impact factor: 3.553

6.  Cefotaxime and desacetyl cefotaxime kinetics in renal impairment.

Authors:  G R Matzke; P A Abraham; C E Halstenson; W F Keane
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

7.  Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis.

Authors:  C M Bunke; G R Aronoff; M E Brier; R S Sloan; F C Luft
Journal:  Clin Pharmacol Ther       Date:  1983-01       Impact factor: 6.875

8.  Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.

Authors:  H C Albin; F M Demotes-Mainard; J L Bouchet; G A Vincon; C Martin-Dupont
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

9.  Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.

Authors:  R Wise; N Wright; P J Wills
Journal:  Antimicrob Agents Chemother       Date:  1981-04       Impact factor: 5.191

  9 in total
  2 in total

Review 1.  Cefotaxime. An update of its pharmacology and therapeutic use.

Authors:  P A Todd; R N Brogden
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.

Authors:  R N Brogden; C M Spencer
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.